Prognostic value of cytokine concentrations (tumor necrosis factor-α, interleukin-6, and interleukin-10) and clinical parameters in severe melioidosis

Journal of Infectious Diseases

Volumn 181, Issue 2, 2000, Pages 621-625

  Simpson, Andrew J H ^a,c   Smith, Michael D ^a,c,e   Jan Weverling, Gerrit ^d   Suputtamongkol, Yupin ^a,f   Angus, Brian J ^a,c   Chaowagul, Wipada ^b   White, Nicholas J ^a,c   Van Deventer, Sander J H ^d   Prins, Jan M ^d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b Sappasitthiprasong Hospital   (Thailand)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e TAUNTON AND SOMERSET HOSPITAL   (United Kingdom)

^f MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MELIOIDOSIS; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APACHE; BACTEREMIA; BIOLOGICAL MARKERS; BURKHOLDERIA PSEUDOMALLEI; CEFTAZIDIME; CEPHALOSPORINS; CYTOKINES; FEMALE; HUMANS; IMIPENEM; INTERLEUKIN-10; INTERLEUKIN-6; LACTATES; LOGISTIC MODELS; MALE; MELIOIDOSIS; MIDDLE AGED; PROGNOSIS; THIENAMYCINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034048834     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315271     Document Type: Article

References (28)

1. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996; 125:680-7.
2. Reinhart K, Wiegand-Löhnert C, Grimminger F, et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24:733-42.
3. Doughty L, Carcillo JA, Kaplan S, Janosky J. The compensatory anti-inflammatory cytokine interleukin 10 response in pediatric sepsis-induced multiple organ failure. Chest 1998; 113:1625-31.
4. van Dissel JT, van Langevelde P, Westendorp RGJ, Kwappenberg K, Frölich M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998; 351:950-3.
5. Casey LC, Balk RA, Bone RC. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome. Ann Intern Med 1993; 119:771-8.
6. Calandra T, Baumgartner J-D, Grau GE, et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-α, and interferon-γ in the serum of patients with septic shock. J Infect Dis 1990; 161:982-7.
7. Wortel CH, von der Möhlen MAM, van Deventer SJH, et al. Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels, J Infect Dis 1992; 166:1367-74.
8. Hack CE, De Groot ER, Felt-Bersma RJF, et al. Increased plasma levels of interleukin-6 in sepsis. Blood 1989; 74:1704-10.
9. Lehmann AK, Halstensen A, Sornes S, Rokke O, Waage A. High levels of interleukin 10 in serum are associated with fatality in meningococcal disease. Infect Immun 1995; 63:2109-12.
10. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987; 1:355-7.
11. Derkx B, Marchant A, Goldman M, Bijlmer R, van Deventer S. High levels of interleukin-10 during the initial phase of fulminant meningococcal septic shock. J Infect Dis 1995; 171:229-32.
12. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock: association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 1989; 169:333-8.
13. Calandra T, Gerain J, Heumann D, Baumgartner JD, Glauser MP, and the Swiss-Dutch J5 Immunoglobulin Study Group. High circulating levels of interleukin-6 in patients with septic shock: evolution during sepsis, prognostic value, and interplay with other cytokines. Am J Med 1991; 91:23-9.
14. Chaowagul W, White NJ, Dance DAB, et al. Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis 1989; 159:890-9.
15. Simpson AJH, Suputtamongkol Y, Smith MD, et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin Infect Dis 1999; 29:381-7.
16. Walsh AL, Wuthiekanun V. The laboratory diagnosis of melioidosis. Br J Biomed Sci 1996; 53:249-53.
17. White NJ, Dance DAB, Chaowagul W, Wattanagoon Y, Wuthiekanun V, Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime. Lancet 1989; ii:697-701.
18. Suputtamongkol Y, Rajchanuwong A, Chaowagul W, et al. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin Infect Dis 1994; 19:846-53.
19. Vincent J-L. Search for effective immunomodulating strategies against sepsis. Lancet 1998; 351:922-3.
20. Friedland JS, Suputtamongkol Y, Remick DG, et al. Prolonged elevation of interleukin-8 and interleukin-6 concentrations in plasma and of leukocyte interleukin-8 mRNA levels during septicemic and localized Pseudomonas pseudomallei infection. Infect Immun 1992; 60:2402-8.
21. Brown AE, Dance DAB, Suputtamongkol Y, et al. Immune cell activation in melioidosis: increased serum levels of interferon-γ and soluble interleukin-2 receptors without change in soluble CD8 protein. J Infect Dis 1991; 163:1145-8.
22. Suputtamongkol Y, Kwiatkowski D, Dance DAB, Chaowagul W, White NJ. Tumor necrosis factor in septicemic melioidosis. J Infect Dis 1992; 165:561-4.
23. Westendorp RGJ, Langermans JAM, Huizinga TWJ, et al. Genetic influence on cytokine production and fatal meningococcal disease. Lancet 1997; 349:170-3.
24. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-29.
25. Day NPJ, Hien TT, Schollaardt T, et al. The prognostic and pathophysiologic role of pro- and antiinflammatory cytokines in severe malaria. J Infect Dis 1999; 180:1288-97.
26. Suter PM, Suter S, Girardin E, Roux-Lombard P, Grau GE, Dayer JM. High bronchoalveolar levels of tumor necrosis factor and its inhibitors, interleukin-1, interferon, and elastase, in patients with adult respiratory distress syndrome after trauma, shock, or sepsis. Am Rev Respir Dis 1992; 145:1016-22.
27. Presterl E, Staudinger T, Pettermann M, et al. Cytokine profile and correlation to the APACHE III and MPM II scores in patients with sepsis. Am J Respir Crit Care Med 1997; 156:825-32.
28. Cohen J, Abraham E. Microbiologic findings and correlations with serum tumor necrosis factor-α in patients with severe sepsis and septic shock. J Infect Dis 1999; 180:116-21.